Taken together, these studies suggest that eIF4E represents a promising candidate for the research on ovarian tumors, whereas downregulating eIF4E expression might be a useful and feasible approach to improve the therapeutic responsiveness of ovarian cancer. Here, EIF4E is linked to ovarian carcinoma.